EP1097147A4 - Nouveaux inhibiteurs de l'angiogenese - Google Patents
Nouveaux inhibiteurs de l'angiogeneseInfo
- Publication number
- EP1097147A4 EP1097147A4 EP99937204A EP99937204A EP1097147A4 EP 1097147 A4 EP1097147 A4 EP 1097147A4 EP 99937204 A EP99937204 A EP 99937204A EP 99937204 A EP99937204 A EP 99937204A EP 1097147 A4 EP1097147 A4 EP 1097147A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- angiogenesis inhibitors
- novel angiogenesis
- novel
- inhibitors
- angiogenesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9228598P | 1998-07-10 | 1998-07-10 | |
| US92285P | 1998-07-10 | ||
| GB9822700 | 1998-10-16 | ||
| GBGB9822700.2A GB9822700D0 (en) | 1998-10-16 | 1998-10-16 | Novel angiogenesis inhibitors |
| PCT/US1999/015200 WO2000002871A1 (fr) | 1998-07-10 | 1999-07-06 | Nouveaux inhibiteurs de l'angiogenese |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1097147A1 EP1097147A1 (fr) | 2001-05-09 |
| EP1097147A4 true EP1097147A4 (fr) | 2001-11-21 |
Family
ID=26314531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP99937204A Withdrawn EP1097147A4 (fr) | 1998-07-10 | 1999-07-06 | Nouveaux inhibiteurs de l'angiogenese |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1097147A4 (fr) |
| JP (1) | JP2002520324A (fr) |
| AU (1) | AU747427B2 (fr) |
| CA (1) | CA2336848A1 (fr) |
| WO (1) | WO2000002871A1 (fr) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2312860C2 (ru) | 1999-04-15 | 2007-12-20 | Бристол-Маерс Сквибб Компани | Циклические ингибиторы протеинтирозинкиназ |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| DE10021246A1 (de) * | 2000-04-25 | 2001-10-31 | Schering Ag | Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel |
| ATE430742T1 (de) | 2000-12-21 | 2009-05-15 | Smithkline Beecham Corp | Pyrimidinamine als angiogenesemodulatoren |
| ATE318812T1 (de) | 2000-12-21 | 2006-03-15 | Bristol Myers Squibb Co | Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie |
| US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| US6693134B2 (en) | 2001-05-29 | 2004-02-17 | Chemokine Therapeutics Corporation | Bicyclic aromatic chemokine receptor ligands |
| US7265134B2 (en) | 2001-08-17 | 2007-09-04 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| CA2483084A1 (fr) | 2002-05-02 | 2003-11-13 | Merck & Co., Inc. | Inhibiteurs de la tyrosine kinase |
| JP4896518B2 (ja) * | 2002-12-13 | 2012-03-14 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | ニコチンアミド系キナーゼ阻害薬 |
| JP5105874B2 (ja) | 2003-07-18 | 2012-12-26 | アムジエン・インコーポレーテツド | 肝細胞増殖因子に対する特異的結合因子 |
| US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
| EP1807077B1 (fr) * | 2004-10-22 | 2016-11-23 | Janssen Pharmaceutica NV | Inhibiteurs de kinase c-fms |
| EP1827434B1 (fr) | 2004-11-30 | 2014-01-15 | Amgen Inc. | Heterocycles substitues et leurs procedes d'utilisation |
| US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| AU2007212696B2 (en) | 2006-02-10 | 2011-05-19 | Amgen Inc. | Hydrate forms of AMG706 |
| JP5331681B2 (ja) | 2006-04-20 | 2013-10-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ｃ−ｆｍｓキナーゼの阻害剤 |
| US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| MX2008013533A (es) | 2006-04-20 | 2009-01-15 | Janssen Pharmaceutica Nv | Compuestos heterociclicos como inhibidores de c-fms cinasa. |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| AU2007338792B2 (en) | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
| US7759344B2 (en) | 2007-01-09 | 2010-07-20 | Amgen Inc. | Bis-aryl amide derivatives and methods of use |
| GB0701426D0 (en) * | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
| WO2008103277A2 (fr) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Cétones d'hétérocyclyle contenant de l'azote et procédés d'utilisation |
| CL2008002444A1 (es) | 2007-08-21 | 2009-09-04 | Amgen Inc | Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente. |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| EP2250160B1 (fr) | 2008-01-25 | 2015-11-11 | Millennium Pharmaceuticals, Inc. | Dérivés de thiophène et leur utilisation comme inhibiteurs de phosphatidylinositol 3-kinase (pi3k) |
| EP2107054A1 (fr) * | 2008-04-01 | 2009-10-07 | Università Degli Studi Di Milano - Bicocca | Composés antiprolifératives et ses utilisations thérapeutiques |
| US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| CA2750935A1 (fr) | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryles et applications associees |
| WO2011161217A2 (fr) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Ciblage du vegfr2 |
| US9062038B2 (en) | 2010-08-11 | 2015-06-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| MA34797B1 (fr) | 2010-08-11 | 2014-01-02 | Millennium Pharm Inc | Hétéroaryles et leurs utilisations |
| EP2603216A4 (fr) * | 2010-08-11 | 2013-12-18 | Millennium Pharm Inc | Hétéroaryles et utilisations |
| EP2627181A4 (fr) | 2010-10-13 | 2014-03-19 | Millennium Pharm Inc | Hétéroaryles et utilisations de ceux-ci |
| DK2688887T3 (en) | 2011-03-23 | 2015-06-29 | Amgen Inc | DEHYDRATED tricyclic DUALINHIBITORER OF CDK 4/6 AND FLT3 |
| AU2012259335B2 (en) * | 2011-05-23 | 2017-03-16 | Merck Patent Gmbh | Thiazole derivatives |
| US9745288B2 (en) | 2011-08-16 | 2017-08-29 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
| EP2882757B1 (fr) | 2012-08-07 | 2016-10-05 | Janssen Pharmaceutica, N.V. | Procédé pour la préparation de dérivés d'ester hétérocyclique |
| US9505749B2 (en) | 2012-08-29 | 2016-11-29 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| CN104860885B (zh) * | 2014-02-24 | 2017-11-17 | 中国科学院上海药物研究所 | 萘酰胺类化合物、其制备方法和用途 |
| EP3242934B1 (fr) | 2015-01-08 | 2021-08-18 | The Board of Trustees of the Leland Stanford Junior University | Facteurs et cellules pour l'induction d'os, de moelle osseuse et de cartilage |
| WO2016202935A1 (fr) | 2015-06-19 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Inhibiteurs de transport du glucose |
| RS62456B1 (sr) | 2016-12-22 | 2021-11-30 | Amgen Inc | Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| SG11202001499WA (en) | 2017-09-08 | 2020-03-30 | Amgen Inc | Inhibitors of kras g12c and methods of using the same |
| EP3788038B1 (fr) | 2018-05-04 | 2023-10-11 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| US11045484B2 (en) | 2018-05-04 | 2021-06-29 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| WO2019217691A1 (fr) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Inhibiteurs de kras g12c pour le traitement du cancer |
| US11096939B2 (en) | 2018-06-01 | 2021-08-24 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| EP3802537A1 (fr) | 2018-06-11 | 2021-04-14 | Amgen Inc. | Inhibiteurs de kras g12c pour le traitement du cancer |
| MX2020012261A (es) | 2018-06-12 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer. |
| JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| CA3117222A1 (fr) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procedes d'utilisation |
| ES2953821T3 (es) | 2018-12-20 | 2023-11-16 | Amgen Inc | Inhibidores de KIF18A |
| MA54546A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
| PE20211475A1 (es) | 2018-12-20 | 2021-08-05 | Amgen Inc | Inhibidores de kif18a |
| MA54547A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
| JP2022522777A (ja) | 2019-03-01 | 2022-04-20 | レボリューション メディシンズ インコーポレイテッド | 二環式ヘテロアリール化合物及びその使用 |
| US20230096028A1 (en) | 2019-03-01 | 2023-03-30 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| EP3738593A1 (fr) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosage d'inhibiteur de kras pour le traitement de cancers |
| EP3972973A1 (fr) | 2019-05-21 | 2022-03-30 | Amgen Inc. | Formes à l'état solide |
| AU2020324963A1 (en) | 2019-08-02 | 2022-02-24 | Amgen Inc. | KIF18A inhibitors |
| CN114401953A (zh) | 2019-08-02 | 2022-04-26 | 美国安进公司 | Kif18a抑制剂 |
| US20220372018A1 (en) | 2019-08-02 | 2022-11-24 | Amgen Inc. | Kif18a inhibitors |
| WO2021026098A1 (fr) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Inhibiteurs de kif18a |
| WO2021081212A1 (fr) | 2019-10-24 | 2021-04-29 | Amgen Inc. | Dérivés de pyridopyrimidine utiles en tant qu'inhibiteurs de kras g12c et de kras g12d dans le traitement du cancer |
| EP4054719A1 (fr) | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| CA3159559A1 (fr) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| TW202132314A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| PE20230249A1 (es) | 2019-11-08 | 2023-02-07 | Revolution Medicines Inc | Compuestos de heteroarilo biciclicos y usos de estos |
| AR120456A1 (es) | 2019-11-14 | 2022-02-16 | Amgen Inc | Síntesis mejorada del compuesto inhibidor de g12c de kras |
| WO2021097212A1 (fr) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Synthèse améliorée de composé inhibiteur de kras g12c |
| JP2023505100A (ja) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | 共有ｒａｓ阻害剤及びその使用 |
| BR112022010086A2 (pt) | 2020-01-07 | 2022-09-06 | Revolution Medicines Inc | Dosagem do inibidor de shp2 e métodos de tratamento de câncer |
| CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
| AU2021344830A1 (en) | 2020-09-03 | 2023-04-06 | Revolution Medicines, Inc. | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
| KR20230067635A (ko) | 2020-09-15 | 2023-05-16 | 레볼루션 메디슨즈, 인크. | 암의 치료에서 ras 억제제로서 인돌 유도체 |
| CN117396472A (zh) | 2020-12-22 | 2024-01-12 | 上海齐鲁锐格医药研发有限公司 | Sos1抑制剂及其用途 |
| CN117500811A (zh) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | 共价ras抑制剂及其用途 |
| CR20230570A (es) | 2021-05-05 | 2024-01-22 | Revolution Medicines Inc | Inhibidores de ras |
| WO2022235870A1 (fr) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Inhibiteurs de ras pour le traitement du cancer |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
| EP4227307A1 (fr) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Composés pyrazolopyrazine en tant qu'inhibiteurs de shp2 |
| WO2023172940A1 (fr) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Méthodes de traitement du cancer du poumon réfractaire immunitaire |
| WO2023240263A1 (fr) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Inhibiteurs de ras macrocycliques |
| WO2024081916A1 (fr) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Méthodes de traitement de cancers à l'aide de dérivés d'isoquinoline ou de 6-aza-quinoléine |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5104889A (en) * | 1986-08-04 | 1992-04-14 | Otsuka Pharmaceutical Factory, Inc. | Thiazole derivatives |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1497536A (en) * | 1973-12-17 | 1978-01-12 | Lilly Industries Ltd | 2-acylaminooxazoles methods for their preparation and their use |
| EP0321115B1 (fr) * | 1987-12-14 | 1991-08-14 | Sawai Pharmaceutical Co., Ltd. | Carboxamides contenant un noyau tétrazole et un noyau thiazole et leur utilisation |
-
1999
- 1999-07-06 WO PCT/US1999/015200 patent/WO2000002871A1/fr not_active Application Discontinuation
- 1999-07-06 JP JP2000559102A patent/JP2002520324A/ja not_active Withdrawn
- 1999-07-06 CA CA002336848A patent/CA2336848A1/fr not_active Abandoned
- 1999-07-06 EP EP99937204A patent/EP1097147A4/fr not_active Withdrawn
- 1999-07-06 AU AU52082/99A patent/AU747427B2/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5104889A (en) * | 1986-08-04 | 1992-04-14 | Otsuka Pharmaceutical Factory, Inc. | Thiazole derivatives |
Non-Patent Citations (5)
| Title |
|---|
| CHEM. HETEROCYCL. COMPD. (ENGL. TRANSL.) (1974), 10(7), 928-931 * |
| DATABASE BEILSTEIN [online] BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT/MAIN, DE; XP002176558, Database accession no. 998965 (BRN) * |
| DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002176557, retrieved from STN Database accession no. 75:35847 * |
| See also references of WO0002871A1 * |
| YAKUGAKU ZASSHI (1971), 91(4), 436-443 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2336848A1 (fr) | 2000-01-20 |
| JP2002520324A (ja) | 2002-07-09 |
| EP1097147A1 (fr) | 2001-05-09 |
| AU5208299A (en) | 2000-02-01 |
| AU747427B2 (en) | 2002-05-16 |
| WO2000002871A1 (fr) | 2000-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1109555A4 (fr) | Nouveaux inhibiteurs d'angiogenese | |
| EP1097147A4 (fr) | Nouveaux inhibiteurs de l'angiogenese | |
| EP0984692A4 (fr) | Nouveaux inhibiteurs d'angiogenese | |
| EP1017682A4 (fr) | Nouveaux inhibiteurs de l'angiogenese | |
| GB9900416D0 (en) | Inhibitors | |
| PL341642A1 (en) | Novel macrolydes | |
| ZA98376B (en) | Sulfamide-metalloprotease inhibitors | |
| GB2321641B (en) | Sulfamide-metalloprotease inhibitors | |
| HUP0202076A3 (en) | Triazine angiogenesis inhibitors | |
| EP1068213A4 (fr) | Nouveaux siloxanes amino-organo-fonctionnels | |
| PL345574A1 (en) | Angiogenesis inhibitors | |
| EP1153022A4 (fr) | Inhibiteurs de protease | |
| GB9821993D0 (en) | Centraliser | |
| GB9816729D0 (en) | Substituted cyclohexylaminopyrimidines | |
| HK1039937A1 (zh) | 取代的3-硫代氨基甲酰基吡唑類化合物 | |
| PL347397A1 (en) | Substituted 3-aryl-pyrazoles | |
| GB2389113B (en) | B-secretase inhibitor | |
| EP1025851A4 (fr) | Inhibiteur de alpha-glucosidase | |
| PL345866A1 (en) | Substituted cyclooctadepsipeptides | |
| HK1039335A1 (zh) | 取代的苯甲酰基環已二酮類化合物 | |
| GB9800681D0 (en) | Novel angiogenesis inhibitors | |
| GB9810544D0 (en) | Novel angiogenesis inhibitors | |
| GB9822700D0 (en) | Novel angiogenesis inhibitors | |
| EP1354589A4 (fr) | Inhibiteurs d'angiogenese | |
| GB9803416D0 (en) | Inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20010212 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
| RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7C 07D 263/48 A, 7C 07D 277/46 B, 7A 61K 31/42 B, 7A 61K 31/425 B, 7C 07D 413/04 B, 7C 07D 413/14 B |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20011005 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| 17Q | First examination report despatched |
Effective date: 20030918 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20040330 |